Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update – Nasdaq
Week Herald |
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
Nasdaq As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the … Editas Medicine Announces Fourth Quarter and Full Year 2017 … Critical Analysis: OpGen (OPGN) and Editas Medicine (EDIT) Financial Newsletter – Zacks |
